Articles
XM Satellite Radio News
ReachMD Broadcasts First-of-its-Kind Physician Peer-Peer Discussion on ENHANCE Trial
Moderated by
The ENHANCE trial is a multinational, randomized, double-blind, trial that examines the effects of the highest approved dose of VYTORIN/INEGY versus the highest approved dose of simvastatin 80 mg alone in patients with Heterozygous Familial Hypercholesterolemia (HeFH). The study was made public by Merck/Schering-Plough Pharmaceuticals.
"The debate around the clinical study on cholesterol drugs has received heavy exposure in a short amount of time," said
The ReachMD Special Report will be easily accessible to a broad medical community through multiple channels throughout the day:
— Satellite Radio - XM Channel 157, beginning at 1:30 p.m. EST — Online Simulcast - www.reachmd.com, beginning at 1:30 p.m. EST — Downloadable Podcast - www.reachmd.com available at 6:00 a.m. EST
About ReachMD
ReachMD, headquartered in Highland Park, Illinois, is a leading provider of advanced healthcare information and education for medical professionals. ReachMD XM 157 remains committed to its mission of delivering highly relevant education, information and communication to medical professionals. The ReachMD XM channel is a new and innovative media vehicle that continues to deliver on this mission. The company's proprietary technology provides the most up-to- date healthcare information in the field through a multi-channel platform that includes satellite radio and online programs accessed through any XM radio, digital media device or PC. Through this platform, healthcare professionals receive the latest information in best practices and new advances in treatment, delivered through convenient and accessible ways. For more information, visit www.reachmd.com.
Contact: Nina Velasquez Kwittken & Company nvelasquez@kwitco.com 646.747.7161
SOURCE ReachMD



